Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia

Duan Li; Qin Ying; Li Yuanda; Zhang Chi; Qu Xiaojuan; Wang Zifan; Baishan•Hunapiya; Wang Fan; Lin Zhiqiang; Lin Guoyue

doi:doi:10.11648/j.sd.20221001.11

| Peer-Reviewed

Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia

Duan Li, Qin Ying, Li Yuanda, Zhang Chi, Qu Xiaojuan, Wang Zifan, Baishan•Hunapiya, Wang Fan, Lin Zhiqiang, Lin Guoyue

Published in Science Discovery (Volume 10, Issue 1)

Received: 7 January 2022 Accepted: Published: 8 January 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective To apply the convalescent plasma of recovered patients with new coronary pneumonia to treat COVID-19 to explore the changes of antibodies IgM and IgG in their bodies and the therapeutic effect. Methods Plasma treatment was performed for COVID-19, and the values of antibody IgM and IgG ct were observed and statistically analyzed. Results (1) 99 cases of rapid development, severe and critically ill patients were transfused with 107250ml plasma, 1083.33ml per capita. The effective rate of blood transfusion was 100% and the cure rate was 100%. (2) The 229 bags of convalescent plasma of the infused convalescent patients have an IgG ct value of 31.61±23.28 and an IgM of 7.19±11.94. (3) The antibody IgG and IgM ct values (68.70±69.14 and 47.89±64.63) of patients in the blood transfusion group were higher than the pre-transfusion ct values (4.46±13.99 and 4.46±13.99), and the differences were significant (p<0.05); The antibody IgM and IgG ct values at discharge of the non-transfusion group were higher than the antibody ct values at admission (p<0.05); in general, the IgM and IgG antibody ct values of the blood transfusion group were 1-3 times higher than those of the non-transfusion group, and there was no difference ( p>0.05), but the levels of antibody IgG and IgM in severe patients in the blood transfusion group were significantly higher than those in the non-transfusion group (P<0.05). (4) The hospitalization days of the fast-growing and severe patients in the blood transfusion group were significantly shorter than those in the non-transfusion group (P<0.05). Conclusion The application of convalescent plasma from patients recovering from new coronary pneumonia to treat COVID-19 can greatly increase the antibody content in severe and critically ill patients, effectively enhance immune function, shorten the length of hospital stay, and speed up the early improvement of the disease.

Published in	Science Discovery (Volume 10, Issue 1)
DOI	10.11648/j.sd.20221001.11
Page(s)	1-6
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Novel Coronavirus, New Coronary Pneumonia, Recovered Plasma, Treatment, Antibody/IgM/IgG

References

[1]	王馨语，廖静，陈俊．新型冠状病毒肺炎免疫学特征及免疫治疗策略的研究进展［J］．热带医学杂志.http://kns.cnki.net/kcms/detail/44.1503.R.20200304. 1632.002.html.
[2]	国家卫生健康委办公厅.关于印发新型冠状病毒肺炎诊疗方案（试行第六版）的通知[EB/OL].医政医管局,2020-02-19/2020-02-26.
[3]	国家卫生健康委办公厅.2020年2月17日新闻发布会文字实录[EB/OL].宣传司,2020-02-17/2020-02-26.
[4]	HOFFMANNM, KLEINE-WEBERH, KRÜGERN, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells[J]. bioRxiv, 2020, DOI: 10.1101/2020.01.31.92.9042.
[5]	国家卫生健康委员会.新型冠状病毒肺炎诊疗方案（试行第六版）[EB/OL]. (2020-02-19).[2020-03-02].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
[6]	杨晓明,侯继峰.康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景[J/OL].中国生物制品学杂志,2020,doi:10.13200/j.cnki.cjb.002999.
[7]	Liu Y, Cao W, Sun M, et al. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities[J].Emerg Microbes Infect,2020,9(1):194-206.
[8]	Mellor JD, Brown MP, Irving HR, et al. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer[J].J Hematol Oncol, 2013,6:1.
[9]	Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong [J]. Eur J Clin Microbiol Infect Dis,2005,24(1):44-46.
[10]	Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee[J].J Infect Dis,1999,179 Suppl 1:S18-23.
[11]	FLETCHERTE, FISCHERWA 2ND, JACOB ST. Convalescent plasma for Ebola virus disease［J］.N Engl J Med, 2016, 374 (25): 2499-2500.
[12]	陆贤吉,马幼丽.临床输血不良反应调查分析[J].临床血液学杂志(输血与检验), 2015, 28 (4): 724-725.
[13]	Jongerius I,Porcelijn L,van Beek A E,et al. The role of complement in transfusion-related acute lung injury [J]. Transfus Med Rev, 2019, 33 (4): 236-242.
[14]	原庆，孙凤霞，姜慧敏，王玉光.恢复期血浆治疗在呼吸道冠状病毒感染疫情中的应用进展[J], 2020, 7 (5) :1-4.
[15]	QIU X，HONG C, LI Y, et al. Calreticulin as a hydrophilic chi- meric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus［J］．Mi- crobiol Immunol, 2012, 56 (8): 554-561.
[16]	ZHU Z, DIMITROV AS, CHAKRABORTI S, et al. Develop- ment of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses [J]. Expert Rev Anti In- fect Ther, 2006, 4 (1): 57-66.
[17]	LIU L，WEI Q，LIN Q，et al． Anti-spike IgG causes severe a-cute lung injury by skewing macrophage responses during acute SARS-CoV infection [J]. JCI Insight, 2019, 4 (4). pii:123158.
[18]	FB.B. Influenza pneumonia treated by blood transfusions. [J]. NYMed1919, 109: 765.
[19]	中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-04)[2020-03-04].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[20]	国家卫生健康委办公厅,中央军委后勤保障部卫生局.关于印发新冠肺炎康复者恢复期血浆临床治疗方案(试行第二版)的通知[EB/OL].(2020-03-04). http://www.gov.cn/zhengce/zhengceku/2020-03/05/content_5487145.htm.
[21]	MillerOOMW.Reportofinfluenzatreatedwithserumfromrecoveredcases. [J]. KyMed, 1919, 17: 218-9.
[22]	PM.C.Injectionofwholebloodininfluenza.［J］.BrMed，1919.
[23]	LesneEBP, Saint-GironsF. Plasmatherapyininfluenza. [J]. PresseMed, 1919, 27: 181-2.
[24]	牛培华，谭文杰.中东呼吸综合征抗病毒治疗研究进展[J].病毒学报, 2018, 34 (05): 599-605.
[25]	李剑平，李晓丰，赵立哲，王宏阳，李伟伟，林园，刘景汉.输血相关治疗应用于新冠病毒肺炎救治中的思考[J].临床输血与检验, 2020, 28 (3): 228-231.
[26]	Zhu J, Kim J, Xiao X, et al. Profiling the immune vulnerability landscape of the 2019 Novel Coronavirus[J/OL]. Preprint at https://doi.org/10.1101/2020.02.08.939553 (2020).
[27]	Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses[J].J Med Virol,2020,92(4):424-432.
[28]	Phan T. Novel coronavirus: from discovery to clinical diagnostics［J］.Infect Genet Evol, 2020, 79: 104211.
[29]	宁雅婷，侯欣，陆旻雅，吴宪，李永哲，徐英春．新型冠状病毒血清特异性抗体检测技术应用探讨［J］．协和医学杂志.http://kns.cnki.net/kcms/detail/11.5882.R. 20200305.1652.002.html.
[30]	何超,江虹,谢轶,等.新型冠状病毒肺炎诊治的实验室检验路径探讨［J/OL］.中国呼吸与危重监护杂志,2020. http://kns.cnki.net/kcms/detail/51.1631.R.20200221.1322. 002.html.［Epub ahead of print］.

Cite This Article

Plain Text BibTeX RIS

APA Style

Duan Li, Qin Ying, Li Yuanda, Zhang Chi, Qu Xiaojuan, et al. (2022). Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia. Science Discovery, 10(1), 1-6. https://doi.org/10.11648/j.sd.20221001.11

Copy | Download

ACS Style

Duan Li; Qin Ying; Li Yuanda; Zhang Chi; Qu Xiaojuan, et al. Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia. Sci. Discov. 2022, 10(1), 1-6. doi: 10.11648/j.sd.20221001.11

Copy | Download

AMA Style

Duan Li, Qin Ying, Li Yuanda, Zhang Chi, Qu Xiaojuan, et al. Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia. Sci Discov. 2022;10(1):1-6. doi: 10.11648/j.sd.20221001.11

Copy | Download

@article{10.11648/j.sd.20221001.11,
  author = {Duan Li and Qin Ying and Li Yuanda and Zhang Chi and Qu Xiaojuan and Wang Zifan and Baishan•Hunapiya and Wang Fan and Lin Zhiqiang and Lin Guoyue},
  title = {Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia},
  journal = {Science Discovery},
  volume = {10},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.sd.20221001.11},
  url = {https://doi.org/10.11648/j.sd.20221001.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20221001.11},
  abstract = {Objective To apply the convalescent plasma of recovered patients with new coronary pneumonia to treat COVID-19 to explore the changes of antibodies IgM and IgG in their bodies and the therapeutic effect. Methods Plasma treatment was performed for COVID-19, and the values of antibody IgM and IgG ct were observed and statistically analyzed. Results (1) 99 cases of rapid development, severe and critically ill patients were transfused with 107250ml plasma, 1083.33ml per capita. The effective rate of blood transfusion was 100% and the cure rate was 100%. (2) The 229 bags of convalescent plasma of the infused convalescent patients have an IgG ct value of 31.61±23.28 and an IgM of 7.19±11.94. (3) The antibody IgG and IgM ct values (68.70±69.14 and 47.89±64.63) of patients in the blood transfusion group were higher than the pre-transfusion ct values (4.46±13.99 and 4.46±13.99), and the differences were significant (p0.05), but the levels of antibody IgG and IgM in severe patients in the blood transfusion group were significantly higher than those in the non-transfusion group (P<0.05). (4) The hospitalization days of the fast-growing and severe patients in the blood transfusion group were significantly shorter than those in the non-transfusion group (P<0.05). Conclusion The application of convalescent plasma from patients recovering from new coronary pneumonia to treat COVID-19 can greatly increase the antibody content in severe and critically ill patients, effectively enhance immune function, shorten the length of hospital stay, and speed up the early improvement of the disease.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia
AU  - Duan Li
AU  - Qin Ying
AU  - Li Yuanda
AU  - Zhang Chi
AU  - Qu Xiaojuan
AU  - Wang Zifan
AU  - Baishan•Hunapiya
AU  - Wang Fan
AU  - Lin Zhiqiang
AU  - Lin Guoyue
Y1  - 2022/01/08
PY  - 2022
N1  - https://doi.org/10.11648/j.sd.20221001.11
DO  - 10.11648/j.sd.20221001.11
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20221001.11
AB  - Objective To apply the convalescent plasma of recovered patients with new coronary pneumonia to treat COVID-19 to explore the changes of antibodies IgM and IgG in their bodies and the therapeutic effect. Methods Plasma treatment was performed for COVID-19, and the values of antibody IgM and IgG ct were observed and statistically analyzed. Results (1) 99 cases of rapid development, severe and critically ill patients were transfused with 107250ml plasma, 1083.33ml per capita. The effective rate of blood transfusion was 100% and the cure rate was 100%. (2) The 229 bags of convalescent plasma of the infused convalescent patients have an IgG ct value of 31.61±23.28 and an IgM of 7.19±11.94. (3) The antibody IgG and IgM ct values (68.70±69.14 and 47.89±64.63) of patients in the blood transfusion group were higher than the pre-transfusion ct values (4.46±13.99 and 4.46±13.99), and the differences were significant (p0.05), but the levels of antibody IgG and IgM in severe patients in the blood transfusion group were significantly higher than those in the non-transfusion group (P<0.05). (4) The hospitalization days of the fast-growing and severe patients in the blood transfusion group were significantly shorter than those in the non-transfusion group (P<0.05). Conclusion The application of convalescent plasma from patients recovering from new coronary pneumonia to treat COVID-19 can greatly increase the antibody content in severe and critically ill patients, effectively enhance immune function, shorten the length of hospital stay, and speed up the early improvement of the disease.
VL  - 10
IS  - 1
ER  -

Copy | Download

Author Information

Duan Li

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Qin Ying

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Li Yuanda

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Zhang Chi

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Qu Xiaojuan

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Wang Zifan

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Baishan•Hunapiya
Wang Fan

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Lin Zhiqiang

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China
Lin Guoyue

Department of Laboratory Medicine, Xinjiang Medical University, The Eighth Affiliated Hospital, Urumqi, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Duan Li, Qin Ying, Li Yuanda, Zhang Chi, Qu Xiaojuan, et al. (2022). Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia. Science Discovery, 10(1), 1-6. https://doi.org/10.11648/j.sd.20221001.11

Copy | Download

ACS Style

Duan Li; Qin Ying; Li Yuanda; Zhang Chi; Qu Xiaojuan, et al. Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia. Sci. Discov. 2022, 10(1), 1-6. doi: 10.11648/j.sd.20221001.11

Copy | Download

AMA Style

Duan Li, Qin Ying, Li Yuanda, Zhang Chi, Qu Xiaojuan, et al. Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia. Sci Discov. 2022;10(1):1-6. doi: 10.11648/j.sd.20221001.11

Copy | Download

@article{10.11648/j.sd.20221001.11,
  author = {Duan Li and Qin Ying and Li Yuanda and Zhang Chi and Qu Xiaojuan and Wang Zifan and Baishan•Hunapiya and Wang Fan and Lin Zhiqiang and Lin Guoyue},
  title = {Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia},
  journal = {Science Discovery},
  volume = {10},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.sd.20221001.11},
  url = {https://doi.org/10.11648/j.sd.20221001.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20221001.11},
  abstract = {Objective To apply the convalescent plasma of recovered patients with new coronary pneumonia to treat COVID-19 to explore the changes of antibodies IgM and IgG in their bodies and the therapeutic effect. Methods Plasma treatment was performed for COVID-19, and the values of antibody IgM and IgG ct were observed and statistically analyzed. Results (1) 99 cases of rapid development, severe and critically ill patients were transfused with 107250ml plasma, 1083.33ml per capita. The effective rate of blood transfusion was 100% and the cure rate was 100%. (2) The 229 bags of convalescent plasma of the infused convalescent patients have an IgG ct value of 31.61±23.28 and an IgM of 7.19±11.94. (3) The antibody IgG and IgM ct values (68.70±69.14 and 47.89±64.63) of patients in the blood transfusion group were higher than the pre-transfusion ct values (4.46±13.99 and 4.46±13.99), and the differences were significant (p0.05), but the levels of antibody IgG and IgM in severe patients in the blood transfusion group were significantly higher than those in the non-transfusion group (P<0.05). (4) The hospitalization days of the fast-growing and severe patients in the blood transfusion group were significantly shorter than those in the non-transfusion group (P<0.05). Conclusion The application of convalescent plasma from patients recovering from new coronary pneumonia to treat COVID-19 can greatly increase the antibody content in severe and critically ill patients, effectively enhance immune function, shorten the length of hospital stay, and speed up the early improvement of the disease.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Study on the Changes of Antibody IgM and IgG Based on the Plasma Treatment of COVID-19 in Patients with New Coronary Pneumonia
AU  - Duan Li
AU  - Qin Ying
AU  - Li Yuanda
AU  - Zhang Chi
AU  - Qu Xiaojuan
AU  - Wang Zifan
AU  - Baishan•Hunapiya
AU  - Wang Fan
AU  - Lin Zhiqiang
AU  - Lin Guoyue
Y1  - 2022/01/08
PY  - 2022
N1  - https://doi.org/10.11648/j.sd.20221001.11
DO  - 10.11648/j.sd.20221001.11
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20221001.11
AB  - Objective To apply the convalescent plasma of recovered patients with new coronary pneumonia to treat COVID-19 to explore the changes of antibodies IgM and IgG in their bodies and the therapeutic effect. Methods Plasma treatment was performed for COVID-19, and the values of antibody IgM and IgG ct were observed and statistically analyzed. Results (1) 99 cases of rapid development, severe and critically ill patients were transfused with 107250ml plasma, 1083.33ml per capita. The effective rate of blood transfusion was 100% and the cure rate was 100%. (2) The 229 bags of convalescent plasma of the infused convalescent patients have an IgG ct value of 31.61±23.28 and an IgM of 7.19±11.94. (3) The antibody IgG and IgM ct values (68.70±69.14 and 47.89±64.63) of patients in the blood transfusion group were higher than the pre-transfusion ct values (4.46±13.99 and 4.46±13.99), and the differences were significant (p0.05), but the levels of antibody IgG and IgM in severe patients in the blood transfusion group were significantly higher than those in the non-transfusion group (P<0.05). (4) The hospitalization days of the fast-growing and severe patients in the blood transfusion group were significantly shorter than those in the non-transfusion group (P<0.05). Conclusion The application of convalescent plasma from patients recovering from new coronary pneumonia to treat COVID-19 can greatly increase the antibody content in severe and critically ill patients, effectively enhance immune function, shorten the length of hospital stay, and speed up the early improvement of the disease.
VL  - 10
IS  - 1
ER  -

Copy | Download